Munich – Treasury Intelligence Solutions GmbH (TIS) has announced that it has signed a binding agreement to sell a majority stake to global investment firm Marlin Equity Partners (Marlin). TIS, a global leader in cloud-native cash management, liquidity and payment solutions, will use the investment to which Marlin has committed under the terms of the deal to drive forward growth of the company and expand the product range. The transaction is expected to complete in the second quarter of 2024. TIS co-founder Jörg Wiemer, Aquiline Capital Partners LP and the management team will retain a significant minority interest in the company.A CMS team headed by partner Dr Jessica Mo­haupt-Schneider and counsel Dr Christoph Küster advised both the company and the management team on specific legal aspects of concluding the agreement. The company and its management team have thus again relied on CMS’s expertise, after a CMS team recently worked on the acquisition of Cashforce, a Belgian fintech start-up offering AI-powered cash management and cash forecasting solutions. CMS Germany Dr Jessica Mo­haupt-Schneider, Lead Partner Dr Christoph Küster, Lead Counsel Dr Tilman Weichert, Part­ner Mar­i­elouise Emmer, Senior As­so­ci­ate Mat­thi­as Unger, Senior Associate Maria Kucher, Associate, all Corporate/M&A Jörg Schrade, Partner, TaxPress Con­tact presse@cms-hs. com

Munich – CMS advises the sellers of Cardior Pharmaceuticals in the potential acquisition of the company by Novo Nordisk. Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions. It is expected to happen in the second quarter of 2024.A CMS team headed by Lead Partners Stefan-Ulrich Müller, Dr Tilman Weichert and Jörg Schrade advised the sellers of Cardior Pharmaceuticals on all legal aspects of the transaction. Cardior Pharmaceuticals GmbH, based in Hannover, Germany, is a leading clinical-stage bio­phar­ma­ceut­ic­al company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. CMS Germany Stefan-Ulrich Müller, Lead Partner Dr Tilman Weichert, Lead Partner Dr Michael Wangemann, Partner Dr Kai Wallisch, Partner Dr Thomas Mühl, Principal Coun­sel Se­basti­an Hummel, Senior As­so­ci­ate Vikt­or­ia Barthel, Senior As­so­ci­ate Mar­i­elouise Emmer, Senior Associate Dr Carl-Friedrich Thoma, Senior Associate Dr Stefan Kühl, Senior Associate Dr Alexander Weinhold, Senior Associate Maria Kucher, Associate Jonas Ohmann, Associate Dr Josephine Doll, Associate Dr Christian Seeburger, Associate Sonja Schanze, Associate, all Corporate/M&A Dr Marie-Luisa Loheide, Associate, Private Clients Jörg Schrade, Lead Partner Eduard Kosavtsev, Senior Associate, both Tax Stefan Lehr, Partner, Antitrust, Competition & Trade Stefan Lüft, Partner, IP Dr Benedikt Forschner, Partner, Labor, Employment & Pensions Dr Markus Kaulartz, Partner Dr Fiona Savary, Counsel Dr Felix Glocker, Senior Associate, all TMC Dr Tilman Niedermaier, Partner Susanne Schwalb, Partner, both Dispute ResolutionPress Con­tact presse@cms-hs. com

Munich – Munich-based biotech company Tubulis has announced the successful completion of its extended and over-subscribed Series B2 round of financing, which raised EUR 128 million. This latest round was led by EQT Life Sciences and Swiss biotech investor Nextech Invest Ltd., representing funds that it manages. Other investors included US funds Frazier Life Sciences and Deep Track Capital along with all the existing investors, including Andera Partners, BioMedPartners, Fund+, Bayern Kapital’s ScaleUp-Fonds Bayern, Evotec, coparion, Seventure Partners, Occident and High-Tech Gründerfonds (HTGF). Tubulis will use the capital raised to develop the firm’s pipeline of next-generation antibody-drug conjugates (ADCs). The aim is also to complete the first clinical evaluation of its two drug candidates and to drive forward the company’s planned US expansion.A CMS team headed by partner Stefan-Ulrich Müller advised Tubulis on all legal aspects of the Series B2 financing. The team led by Stefan-Ulrich Müller has been advising Tubulis for several years now, including on the preceding EUR 60 million Series B round of financing. This work is another excellent example of the wide-ranging advisory services that CMS offers in the Lifesciences & Healthcare sector. CMS Germany Stefan-Ulrich Müller, Lead Part­ner Se­basti­an Hummel, Senior Associate Maria Kucher, Associate, all Corporate/M&A, Venture Capital Stefan Lüft, Partner, Intellectual Property Jörg Schrade, Partner, Tax Stefan Lehr, Partner, Antitrust, Competition & TradePress Con­tact presse@cms-hs. com

Munich – Family-owned firm Pfeifer & Langen has taken a majority stake in Rügenwalder Mühle, a branded manufacturer that is considered a pioneer in vegetarian/vegan alternatives to meat and sausages...

Munich – Freudenberg Home and Cleaning GmbH, an international supplier of branded cleaning products and systems as well as laundry care products, has acquired VERMOP Salmon GmbH, a German manufacturer...